Physician profile
Coreen Murphy
NPI 1861574931
$3,387.21
in general payments reported to CMS, 2019-2025
24 companies · $681 in 2025
The $681 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $135 · 2021: $646 · 2022: $802 · 2023: $517 · 2024: $304 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $713.64 | 2019-2022 | |
| Abbvie INC. | $639.49 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $268.17 | 2022-2024 | Miebo, Vyzulta, Lotemax Sm |
| Eyevance Pharmaceuticals LLC | $201.25 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $190.71 | 2019-2025 | Cequa |
| Alcon Vision LLC | $175.81 | 2022-2025 | Clareon, Tryptyr, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $155.82 | 2019-2020 | |
| Oyster Point Pharma, INC. | $138.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $114.60 | 2019-2021 | |
| Rxsight INC | $113.89 | 2023 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Harrow Eye, LLC | $108.06 | 2024-2025 | Vevye |
| Glaukos Corporation | $100.74 | 2023-2025 | Ce-Marked Kxla System, Idosetr, Istent Infinite |
| Tarsus Pharmaceuticals, INC. | $97.20 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $94.43 | 2019-2022 | |
| Biotissue Holdings INC. | $60.27 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $51.71 | 2021-2022 | |
| Shire North American Group INC | $44.17 | 2019 | |
| Samsara Vision | $35.84 | 2023 | |
| Dompe US, INC. | $18.59 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $17.71 | 2025 | Syfovre |
| Sight Sciences, INC. | $16.38 | 2025 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $14.61 | 2021 | |
| Quidel Corporation | $9.15 | 2019 | |
| Visioneering Technologies, INC. | $6.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coreen Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.